|Security||ARLZ / Aralez Pharmaceuticals Inc.|
|Institution||Deutsche Bank Ag\|
Deutsche Bank Ag\ reports 23.96% decrease in ownership of ARLZ / Aralez Pharmaceuticals Inc.
May 15, 2018 - Deutsche Bank Ag\ has filed a 13F-HR form disclosing ownership of 281,545 shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) with total holdings valued at $421,000 USD as of March 31, 2018. Deutsche Bank Ag\ had filed a previous 13F-HR on February 14, 2018 disclosing 370,245 shares of Aralez Pharmaceuticals Inc. at a value of $524,000 USD. This represents a change in shares of -23.96 percent and a change in value of -19.66 percent during the quarter.
Other investors with positions similar to Deutsche Bank Ag\ include DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main, Brown Advisory Securities, LLC, JW Asset Management, LLC, Gsa Capital Partners Llp, Dimensional Fund Advisors Lp, and Salzhauer Michael.
Aralez Pharmaceuticals Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry. Deutsche Bank Ag\'s top industries are "Fishing hunting and trapping" (sic 09), "Forestry" (sic 08), and "Legal Services" (sic 81).
The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.
In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.
Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.
2017-10-23 - Asif
Aralez is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Its parent corporation, Aralez Pharmaceuticals Inc., was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on December 2, 2015. its global headquarters is located in Mississauga, Ontario, Canada, its U.S. headquarters is located in Princeton, New Jersey, United States, and its Irish headquarters is located in Dublin, Ireland. Aralez was formed for the purpose of facilitating the business combination of POZEN Inc., a Delaware corporation (“Pozen”), and Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (“Tribute”), which transaction closed on February 5, 2016. On February 5, 2016, pursuant to an Agreement and Plan of Merger and Arr...
as of ET